Telix Buys the Supply Chain Its Pipeline Runs On

ITM was founded in 2004 and has stayed private. It manufactures therapeutic radioisotopes at commercial scale and distributes them across more than 65 countries, covering lutetium-177, actinium-225 and terbium-161. Critically, it is the only producer of globally scaled commercial-grade lutetium-177, supplying both products already on the market and candidates still in clinical development.

That matters for Telix because radiopharmaceuticals fail on supply as readily as on science. Owning the isotope source removes a dependency rather than managing it. The business also pays its own way: ITM delivered US$273 million of revenue in 2025, having grown at a 40% compound annual rate since 2021, and its manufacturing operation is profitable and cash generating. For context on the runway ahead, Telix cites a MEDraysintell forecast putting the global nuclear medicine market at US$41 billion by 2034.

ITM-11 Adds a Completed Phase 3 Program

The deal also brings a late-stage drug candidate. ITM-11, or lutetium-177 edotreotide, targets the somatostatin receptor in gastroenteropancreatic neuroendocrine tumors, known as GEP-NETs. It has completed the Phase 3 COMPETE trial, and a second Phase 3 study in an expanded indication, COMPOSE, is fully enrolled with an interim analysis expected in the first half of 2027.

Managing Director and Group Chief Executive Officer Dr. Christian Behrenbruch framed the merger as positioning Telix at the forefront of consolidation as the industry matures, noting that it expands the late-stage therapeutic pipeline with two completed Phase 3 trials while deepening radioisotope security. If regulators approve ITM-11, Telix expects it to accelerate entry into the commercial therapeutic market and to add high-margin revenue in the near term.

The Price, the Milestones and the Vote

The upfront US$1.65 billion breaks down into US$1.25 billion paid to sellers in 105.8 million Telix shares, priced at a 30-day trailing volume-weighted average of US$11.841 at signing and released as Nasdaq-listed ADRs once escrow periods end; US$302 million of net debt assumed at closing; and US$96 million of management equity rollover and transaction expenses payable by the sellers. Lockup restrictions on the shares issued at closing run up to 15 months.

The contingent US$700 million splits two ways. Up to US$250 million follows FDA approvals of ITM-11 across three indications: US$100 million for G1-G2 GEP-NETs by December 31, 2027, a further US$100 million for G2-G3 GEP-NETs by December 31, 2030, and US$50 million for lung NETs by December 31, 2031. The remaining US$450 million depends on ITM-11 net global sales exceeding US$150 million in FY 2030. Telix may settle any milestone in cash or shares at its election.

On completion, Telix shareholders would hold roughly 76.3% of the combined company and ITM shareholders roughly 23.7%. The Telix board has approved the transaction, and holders of more than 90% of ITM shares had signed on at the time of signing. Closing is targeted by the end of FY 2026 and still requires a Telix shareholder vote under the ASX Listing Rules, with an extraordinary general meeting expected in November 2026, plus regulatory clearances. Management estimates unaudited pro forma 2026 revenue and income for the combined group above US$1.3 billion, and expects a positive EBITDA contribution from 2027 onward, although that expectation assumes targeted synergies are realized and excludes one-off implementation costs.

Strategic Investment Summary

• Merger Agreed: Telix Pharmaceuticals (NASDAQ: TLX) signed a strategic agreement to acquire 100% of ITM Isotope Technologies Munich SE for US$1.65 billion upfront on a cash-free, debt-free basis.
• Supply Secured: ITM is the only producer of globally scaled commercial-grade lutetium-177, also manufactures actinium-225 and terbium-161, and distributes across more than 65 countries.
• Profitable Base: ITM delivered US$273 million of revenue in 2025 at a 40% compound annual growth rate since 2021, from a manufacturing business that is profitable and generates cash.
• Pipeline Addition: ITM-11 has completed the Phase 3 COMPETE trial in GEP-NETs, and the second Phase 3 study, COMPOSE, is fully enrolled with an interim analysis expected in the first half of 2027.
• Milestones Attached: Up to US$700 million more is payable, with up to US$250 million on FDA approvals across three indications and up to US$450 million if ITM-11 net global sales exceed US$150 million in FY 2030.
• Approvals Pending: Telix shareholders would own about 76.3% of the combined company and vote at an extraordinary general meeting expected in November 2026, with closing targeted by the end of FY 2026.

Find out more about the latest corporate developments and financial reports at the Telix investor center.

The post Telix to Acquire ITM for US$1.65 Billion Upfront, Securing the Only Globally Scaled Supply of Lutetium-177 appeared first on PRISM MarketView.

COMTEX_493031438/2927/2026-09-21T11:00:42